A Phase III trial showed that relapsed non-Hodgkin's lymphoma patients who received Cell Therapeutics' immunosuppressant drug pixantrone achieved a high rate of confirmed and unconfirmed remissions compared with those who received standard chemotherapy. The company is planning to file a new-drug application for pixantrone within the first half of the year.

Full Story:
RTT News

Related Summaries